Promega and FUJIFILM Cellular Dynamics Inc. announced recently that they will partner to advance novel assay development for drug discovery.

According to a release, the multi-year licensing agreement will integrate some technologies from the two companies for researchers and scientists to use to develop new biosensor assays in induced pluripotent stem cell (iPSC)-derived cells.

“The market continues to move towards assay formats that best recapitulate human disease, and iPSC-derived cells are a critical part of that movement,” FCDI Senior VIP of Commercial Operations Keith R. Olson said in a statement. “Adding this robust assay technology from Promega to our cells creates a wealth of possibilities for discovery researchers around the world in their efforts to advance medicine.”

Financial terms of the agreement were not released.